162 related articles for article (PubMed ID: 31863835)
1. Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1.
Deyev SM; Vorobyeva A; Schulga A; Abouzayed A; Günther T; Garousi J; Konovalova E; Ding H; Gräslund T; Orlova A; Tolmachev V
Int J Biol Macromol; 2020 Feb; 145():216-225. PubMed ID: 31863835
[TBL] [Abstract][Full Text] [Related]
2. Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1.
Vorobyeva A; Bezverkhniaia E; Konovalova E; Schulga A; Garousi J; Vorontsova O; Abouzayed A; Orlova A; Deyev S; Tolmachev V
Molecules; 2020 Oct; 25(20):. PubMed ID: 33066684
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of Imaging EpCAM Expression in Ovarian Cancer Using Radiolabeled DARPin Ec1.
Vorobyeva A; Konovalova E; Xu T; Schulga A; Altai M; Garousi J; Rinne SS; Orlova A; Tolmachev V; Deyev S
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32392820
[TBL] [Abstract][Full Text] [Related]
4. Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties.
Deyev S; Vorobyeva A; Schulga A; Proshkina G; Güler R; Löfblom J; Mitran B; Garousi J; Altai M; Buijs J; Chernov V; Orlova A; Tolmachev V
Mol Pharm; 2019 Mar; 16(3):995-1008. PubMed ID: 30608701
[TBL] [Abstract][Full Text] [Related]
5. Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.
Vorobyeva A; Sсhulga A; Konovalova E; Güler R; Mitran B; Garousi J; Rinne S; Löfblom J; Orlova A; Deyev S; Tolmachev V
Int J Oncol; 2019 Apr; 54(4):1209-1220. PubMed ID: 30968147
[TBL] [Abstract][Full Text] [Related]
6. Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1.
Deyev SM; Xu T; Liu Y; Schulga A; Konovalova E; Garousi J; Rinne SS; Larkina M; Ding H; Gräslund T; Orlova A; Tolmachev V; Vorobyeva A
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298801
[TBL] [Abstract][Full Text] [Related]
7. Radionuclide Tumor Targeting Using ADAPT Scaffold Proteins: Aspects of Label Positioning and Residualizing Properties of the Label.
Lindbo S; Garousi J; Mitran B; Altai M; Buijs J; Orlova A; Hober S; Tolmachev V
J Nucl Med; 2018 Jan; 59(1):93-99. PubMed ID: 28864631
[TBL] [Abstract][Full Text] [Related]
8. Indirect Radioiodination of DARPin G3 Using N-succinimidyl-
Vorobyeva A; Schulga A; Rinne SS; Günther T; Orlova A; Deyev S; Tolmachev V
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234471
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model.
Xu T; Schulga A; Konovalova E; Rinne SS; Zhang H; Vorontsova O; Orlova A; Deyev SM; Tolmachev V; Vorobyeva A
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769161
[TBL] [Abstract][Full Text] [Related]
10. DARPin Ec1-LMWP protein scaffold in targeted delivery of siRNA molecules through EpCAM cancer stem cell marker.
Babaee N; Talebkhan Garoosi Y; Karimipoor M; Davami F; Bayat E; Safarpour H; Mahboudi F; Barkhordari F
Mol Biol Rep; 2020 Oct; 47(10):7323-7331. PubMed ID: 32979162
[TBL] [Abstract][Full Text] [Related]
11. Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.
Vorobyeva A; Bragina O; Altai M; Mitran B; Orlova A; Shulga A; Proshkina G; Chernov V; Tolmachev V; Deyev S
Contrast Media Mol Imaging; 2018; 2018():6930425. PubMed ID: 29977173
[TBL] [Abstract][Full Text] [Related]
12. Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules.
Rinne SS; Xu T; Dahlsson Leitao C; Ståhl S; Löfblom J; Orlova A; Tolmachev V; Vorobyeva A
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32075258
[TBL] [Abstract][Full Text] [Related]
13. Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins
Larkina M; Varvashenya R; Yuldasheva F; Plotnikov E; Bezverkhniaia E; Tretyakova M; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Belousov M; Orlova A; Tolmachev V; Deyev S
Mol Pharm; 2024 Apr; 21(4):1919-1932. PubMed ID: 38557163
[TBL] [Abstract][Full Text] [Related]
14. Visualization of epithelial cell adhesion molecule-expressing renal cell carcinoma xenografts using designed ankyrin repeat protein Ec1 labelled with
Tolmachev V; Bodenko V; Orlova A; Schulga A; Deyev SM; Vorobyeva A
Oncol Lett; 2023 Jan; 25(1):12. PubMed ID: 36478911
[TBL] [Abstract][Full Text] [Related]
15. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vivo evaluation of technetium and iodine labels on an anti-HER2 affibody for single-photon imaging of HER2 expression in tumors.
Orlova A; Nilsson FY; Wikman M; Widström C; Ståhl S; Carlsson J; Tolmachev V
J Nucl Med; 2006 Mar; 47(3):512-9. PubMed ID: 16513621
[TBL] [Abstract][Full Text] [Related]
17. Optimal composition and position of histidine-containing tags improves biodistribution of
Vorobyeva A; Schulga A; Konovalova E; Güler R; Löfblom J; Sandström M; Garousi J; Chernov V; Bragina O; Orlova A; Tolmachev V; Deyev SM
Sci Rep; 2019 Jun; 9(1):9405. PubMed ID: 31253840
[TBL] [Abstract][Full Text] [Related]
18. DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency.
Stefan N; Martin-Killias P; Wyss-Stoeckle S; Honegger A; Zangemeister-Wittke U; Plückthun A
J Mol Biol; 2011 Nov; 413(4):826-43. PubMed ID: 21963989
[TBL] [Abstract][Full Text] [Related]
19. Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model.
Xu T; Vorobyeva A; Schulga A; Konovalova E; Vorontsova O; Ding H; Gräslund T; Tashireva LA; Orlova A; Tolmachev V; Deyev SM
Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439094
[TBL] [Abstract][Full Text] [Related]
20. Gene delivery to breast cancer by incorporated EpCAM targeted DARPins into AAV2.
Lv YF; Zhang H; Cui Z; Ma CJ; Li YL; Lu H; Wu HY; Yang JL; Cao CY; Sun WZ; Huang XF
BMC Cancer; 2023 Dec; 23(1):1220. PubMed ID: 38082377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
